Recent Quotes (30 days)

You have no recent quotes
chg | %

aTyr Pharma Inc  

(Public, NASDAQ:LIFE)   Watch this stock  
Find more results for LIFE
16.49
0.00 (0.00%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 12.90 - 28.29
Open     -
Vol / Avg. 0.00/154,153.00
Mkt cap 389.73M
P/E     -
Div/yield     -
EPS -1.22
Shares 23.63M
Beta     -
Inst. own 19%
Jun 10, 2015
aTyr Pharma Inc at William Blair Annual Growth Stock Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -90.34% -80.59%
Return on average equity - -
Employees 53 -
CDP Score - -

Address

3545 John Hopkins Ct Ste 250
SAN DIEGO, CA 92121-1115
United States - Map
+1-858-7318389 (Phone)
+1-858-7318394 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using a set of physiological modulators. The Company has discovered approximately 300 Physiocrines, a class of naturally occurring proteins that promotes homeostasis. The Company’s Physiocrines have therapeutic application in various diseases characterized by tissue dysfunction, including severe diseases of the lung, gut, skin, brain and liver. The Company is engaged the development of Resolaris as an intravenous protein therapeutic for the treatment of rare myopathies with an immune component, or RMICs. The Company has developed Resolaris based on its discovery of the Resokine pathway in skeletal muscle tissue, an extracellular pathway in human skeletal muscle tissue associated with activities arising from various Physiocrine regions of the human histidine aminoacyl tRNA synthetase.

Officers and directors

John D. Mendlein Ph.D. Chief Executive Officer and Executive Chairman, Board of Directors
Age: 55
Bio & Compensation  - Reuters
Frederic Chereau President, Chief Operating Officer
Age: 48
Bio & Compensation  - Reuters
Melissa A Ashlock Vice President - External Scientific Alliances and Human Genetics
Age: 57
Bio & Compensation  - Reuters
Kelly Blackburn Vice President - Clinical Affairs
Age: 51
Bio & Compensation  - Reuters
Holly D Chrzanowski Vice President - Enterprise Talent and Organization
Age: 49
Bio & Compensation  - Reuters
Andrew Cubitt Vice President - Product Protection
Age: 52
Bio & Compensation  - Reuters
John C McKew Vice President - Research
Age: 51
Bio & Compensation  - Reuters
Fred Ramsdell Vice President - Immunology
Age: 54
Bio & Compensation  - Reuters
David M Weiner Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
John K. Clarke Non-Executive Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters